Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study of GF-01-01 to Evaluate the Safety and Persistence of GF-CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

NCT06985576 is registered in ClinicalTrials.gov with GenomeFrontier Therapeutics TW Co., Ltd. as lead sponsor.

NCT NCT06985576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06985576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study of GF-01-01 to Evaluate the Safety and Persistence of GF-CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Lead sponsor
GenomeFrontier Therapeutics TW Co., Ltd.
Phase
Observational
Overall status
Enrolling by invitation
Start date
February 26, 2026
Completion date
May 31, 2041
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl - diffuse large b cell lymphoma, follicular lymphoma (fl), high grade b cell lymphoma, primary mediastinal large b-cell lymphoma